Agios Pharmaceuticals, Inc.
AGIO· Nasdaq
AGIOAgios Pharmaceuticals, Inc.
Source filing unavailable
| Metric | Q2 2013 | Q2 2012 |
|---|---|---|
| Revenue | $6.27M | $6.29M |
| Net Income | -$8.62M | -$5.51M |
| EPS Diluted | -$2.80 | -$2.18 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Agios Pharmaceuticals, Inc. · CIK 1439222 · Engraved from SEC EDGAR
